Related Experiment Video
Updated: Aug 9, 2026
22:10
Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
Inverted Fab2s (IFab2s): engineering and expression of novel, dimeric molecules, with a molecular weight of 100 000
R R Speck1, J R Couto, S G Godwin
1Cancer Research Fund of Contra Costa, Walnut Creek, CA 94596, U.S.A.
Molecular Immunology
|October 1, 1996
Summary
A novel engineered antibody fragment, IFab2, was developed for breast cancer therapy. A 21-residue linker facilitated the formation of IFab2 dimers, which retained the original antibody's binding affinity and specificity.
Area of Science:
- Immunotechnology
- Biotechnology
- Cancer Research
Background:
- The development of targeted cancer therapies is crucial for improving patient outcomes.
- Engineered antibody fragments offer potential for enhanced specificity and reduced immunogenicity.
- The BrE-3 antibody has shown promise as an anti-breast cancer therapeutic.
Purpose of the Study:
- To engineer and characterize a novel antibody fragment, IFab2, for potential breast cancer treatment.
- To investigate the role of peptide linker length in the formation of IFab2 dimers.
- To confirm that IFab2 retains the binding characteristics of the parent antibody.
Main Methods:
- Construction of a single gene encoding humanized antibody fragments (VH-CH1 and Vk-Ck) with a peptide linker.
- Expression and purification of IFab2 molecules with varying linker lengths.
- Analysis of multimer formation (monomers, dimers, etc.) using different linker lengths.
- Binding competition assays to assess the affinity and specificity of purified IFab2.
Main Results:
- A 21-residue peptide linker successfully promoted the predominant formation of IFab2 dimers.
- Varying linker lengths influenced the formation of different multimer species.
- Purified IFab2 demonstrated complete retention of affinity and specificity compared to the original BrE-3 monoclonal antibody.
- The engineered IFab2 molecule is expressed from a single gene construct.
Conclusions:
- The engineered IFab2 molecule, utilizing a specific linker length, effectively forms dimers with retained therapeutic potential.
- IFab2 represents a promising candidate for targeted breast cancer therapy due to its preserved binding characteristics.
- This study highlights the successful engineering of functional antibody fragments from a single gene construct.
